Adrenal scintiscanning with NP-59, a new radioiodinated cholesterol agent

J. M. Miles, H. W. Wahner, P. C. Carpenter, R. M. Salassa, R. C. Northcutt

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Adrenal imaging in the past has been limited in its clinical application by the long interval between administration of dose and visualization of adrenal glands. We review our experience with the use of a newer labeling agent, NP-59, in 29 patients with various adrenal disorders and in 4 normal subjects. With this agent, indentification of adrenal lesions is possible with a high degree of accuracy, and diagnostic information is usually available within 48 hours. NP-59 is particularly useful in evaluating primary aldosteronism and selected cases of Cushing's syndrome.

Original languageEnglish (US)
Pages (from-to)321-327
Number of pages7
JournalMayo Clinic proceedings
Issue number5
StatePublished - 1979

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Adrenal scintiscanning with NP-59, a new radioiodinated cholesterol agent'. Together they form a unique fingerprint.

Cite this